Grant ID RP200223
Awarded On February 19, 2020
Title High-Sensitivity 19F MRI for Clinically Translatable Imaging of Adoptive NK Cell Brain Tumor Therapy
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas M.D. Anderson Cancer Center
Principal Investigator/Program Director Konstantin Sokolov
Cancer Sites Brain and Other Nervous System
Contracted Amount $887,713
Lay Summary

Immunotherapy is emerging as an exciting new approach to cancer therapy that often has fewer side effects compared to traditional combinations of radiation, chemotherapy, and surgery. MD Anderson is a leader in NK cell therapy development with more than a dozen active clinical trials including the first in human, FDA-approved, Phase-I clinical trial (NCT02271711) for children with recurrent brain tumors. Unfortunately, little is known about the biodistribution of NK cells after administration. Imaging strategies that allow visualization of their distribution could provide invaluable new information to help guide the development of optimized cancer therapies. 19F perfluorocarbon (PFC)-b...

Read More